UK markets closed
  • FTSE 100

    7,122.32
    -6.89 (-0.10%)
     
  • FTSE 250

    22,646.08
    -38.76 (-0.17%)
     
  • AIM

    1,182.30
    -6.44 (-0.54%)
     
  • GBP/EUR

    1.1690
    -0.0076 (-0.65%)
     
  • GBP/USD

    1.3235
    -0.0067 (-0.50%)
     
  • BTC-GBP

    35,240.92
    -8,077.30 (-18.65%)
     
  • CMC Crypto 200

    1,367.14
    -74.62 (-5.18%)
     
  • S&P 500

    4,538.43
    -38.67 (-0.84%)
     
  • DOW

    34,580.08
    -59.71 (-0.17%)
     
  • CRUDE OIL

    66.22
    -0.28 (-0.42%)
     
  • GOLD FUTURES

    1,782.10
    +21.40 (+1.22%)
     
  • NIKKEI 225

    28,029.57
    +276.20 (+1.00%)
     
  • HANG SENG

    23,766.69
    -22.24 (-0.09%)
     
  • DAX

    15,169.98
    -93.13 (-0.61%)
     
  • CAC 40

    6,765.52
    -30.23 (-0.44%)
     

Real-World Evidence Market Forecast 2020 - 2030: Visiongain Research Inc

·5-min read

Visiongain has published a new report on “Real-World Evidence Market Report Forecast 2020-2030”. Forecasts by Component (Data Sets, Services), Datasets (Clinical Settings Data, Claims Data, Pharmacy Data, Patient-Powered Data, Others), Therapeutic Area (Oncology, Cardiovascular Diseases, Neurology, Immunology, Other Therapeutic Areas), End-Users (Healthcare Payers, Healthcare Providers, Pharmaceutical & Medical Device Companies, Other End-Users), by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), PLUS COVID-19 Recovery Scenarios.

Download Exclusive Sample of Report @ https://www.visiongain.com/report/rwe-solutions-market-2020/#download_sampe_div

COVID-19 Impact on Real-World Evidence Market

The COVID pandemic has impacted this market in a very positive way. There is no such cure for the disease and the vaccines are still in development and trial stages. With the use of real-world evidence (RWE) solutions, the data present is expected to give out positive results. Numerous large vaccine trials have been launched to study the effects on coronavirus, which includes around 30,000 volunteers for most of the trials. But such clinical trials are not capable of offering all the data required by scientists in their pursuit to tame the COVID pandemic. The COVID-19 pandemic has added an urgency to use real-world evidence (RWE) solutions, boosting the market in the coming years. It’s a global scale health crisis, patient records collected every hour can be analyzed and used to offer a better picture of the COVID-19 pandemic.

Market Drivers

Increasing use of Big data in Healthcare Industry

Real-world studies and real-world evidence are gradually becoming significant in offering confirmation and data for effective cure and treatment during clinical practice and trials. Real-world studies use information from electronic health records and claims databases, which offer large datasets from varied patient populations, and are also collecting observational, retrospective, or prospective data from a long time period. They also offer information on the long-term use and safety of drugs mainly relating to rare events, and efficacy of drugs in huge diverse populations, and economic outcomes. Growing use of Bigdata and various algorithms have helped hospitals in the management of many chronic conditions by creating similar construction of algorithms that can codify the management of these conditions. This offers efficient and rapid management of the condition with improved patient experience and a scalable solution that can reduce the burden on primary care physicians.

Get Detailed TOC @ https://www.visiongain.com/report/rwe-solutions-market-2020/#download_sampe_div

Market Opportunities

Long-Term Outlook for Chronic Disease Management

The continuous strong growth in the chronic disease management therapeutics and device technologies is expected to create new opportunities for using real world evidence solutions. There will always be a need for safe and effective therapeutics to more efficiently manage chronic diseases, but the future of the chronic disease management market is not solely dependent upon innovative drugs and biologics. Technological advancements in continuous and remote disease monitoring may reduce the overall cost burden of chronic diseases with improved treatment adherence. New investments in R&D activities, advancements in wearable monitoring and drug delivery are also expected to set new milestones for surgeons and patients. Prophylactic management of the disease, including the adoption of healthier lifestyles, represents great progress and reduces the overall burden of chronic diseases.

Competitive Landscape

Some of the companies profiled in the report include Iqvia, IBM, Pharmaceutical Product Development, PAREXEL, Optum (A Subsidiary of United Health Group, Inc.), PerkinElmer, Icon PLC, Oracle, Cognizant, Syneos Health, Anthem, Clinigen, and Covance Inc.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence

To access the data contained in this document please email contactus@visiongain.com

Information found nowhere else
With this new and exclusive report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your investment, research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Real-World Evidence Market and Leading Companies. You will get the most recent data, opportunities, trends, and predictions.

Find more Visiongain research reports on Pharma Big Data Analytics click on the following links:

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: catherine.walker@visiongain.com

About Visiongain

Visiongain is one of the fastest growing and most innovative, independent, market intelligence around, the company publishes hundreds of market research reports which it adds to its extensive portfolio each year. These reports offer in-depth analysis across 18 industries worldwide. The reports cover a 10-year forecast, are hundreds of pages long, with in depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets, which currently can influence one another, these markets include automotive, aviation, chemicals, cyber, defense, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customized and syndicated market research reports means that you can have a bespoke piece of market intelligence customized to your very own business needs.

Contact:

Catherine Walker
PR at Visiongain Inc.
Tel: + 44 0207 336 6100
USA Tel: + 1 718 682 4567
EU Tel: + 353 1 695 0006
Toll Free: 00-1-646-396-5129
Email: catherine.walker@visiongain.com
Web: https://www.visiongain.com
Follow Us: LinkedIn | Twitter

-

SOURCE Visiongain Limited.


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting